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A b s t r a c t  
Nanoparticles containing luteolin flavonoid were prepared by using interfacial polymer deposition 
following solvent displacement. The formulation was optimized using factorial design. The 
parameters studied were the type of polymer [poly(ε-caprolactone) and poly(lactic-co-glycolic acid)], 
nature oil (isodecyl oleate and oleic acid) and the quantity of luteolin. Nanocapsules and 
nanospheres were also prepared and evaluated. Colloidal suspensions were characterized by 
evaluating pH, the particle size, the zeta potential, the morphological aspect and the kinetic release. 
A new High Performance Liquid Chromatography method was developed and validated in order to 
quantify luteolin in colloidal suspension allowing the analyses of the absolute recovery, entrapment 
efficiency and the kinetic release. The luteolin-absolute recovery ranged from 61.6% to 95%; 
entrapment efficiency was nearly 100% in all formulations and the particle sizes were smaller than 
185.5 nm. The nanoparticles prepared with isodecyl oleate show a negative zeta potential. On the 
other hand, when oleic acid was utilized, the zeta potential was positive. The nanoparticles prepared 
by using isodecyl oleate have a more perfect spherical shape with a regular surface and form, 
homogeneity, and lower size dispersion. Nanocapsules and nanospheres have a similar release 
mechanism of pure diffusion according with Korsmeyer-Peppas’s model. 
Keywords: Luteolin, polymeric nanoparticles, characterization, factorial design, release kinetics. 
 
Introduction 
Since the beginning of human civilization, herbs have been an 
integral part of a human diet and medicine, valued for their 
culinary and medicinal properties. However, with the development 
of patent pharmaceuticals in the first part of the twentieth century, 
herbal medicine lost ground to new synthetic products touted by 
scientists and physicians to be more effective and reliable [1]. 
Nowadays, a new and renovated interest toward herbal medicines 
is observed. Some of the reasons which justify this fact are: (i) the 
sale of herbal medicines and their secure use have considerably 
increased over the last 10 years; (ii) herbal medicines are used to 
treat a wide range of problems; (iii) the development of new 
diseases, with severe complications, for which there is still no 
appropriate treatment; (iv) the belief that herbal remedies are 
innocuous, in contrast to conventional drugs; (v) the idea that 
what is natural can only be good, etc.[2-3]. 
Among herbal medicines, extracts rich in flavonoids have elicited 
particular interest. Flavonoids are naturally-occurring plant 
polyphenols characterized by a diphenylpropane structure (C6- 
 
 
 
C3-C6) found in abundance in vegetables, fruits, nuts, seeds, 
herbs, spices, flowers, red wine and tea. They possess a wide 
range of biological activities and could be used to prevent 
diseases. Research and application of flavonoids in functional 
foods and in nutraceutical and pharmaceutical industries have 
been areas of great interest especially because they demonstrate 
a remarkable array of biochemical and pharmacological actions 
including anti-inflamatory, anti-oxidant, cytostatic, apoptotic and 
estrogenic activities [4-5]. 
Among the flavonoids, luteolin (3’,4’,5,7-tetrahydroxyflavone) 
(Figure 1), found in a wide range of plants such as in celery, 
green pepper, perilla leaf, chamomile tea, broccoli, and carrots, 
exhibits several biochemical activities and capable of enhancing 
insulin sensitivity [6-8]. Furthermore, luteolin is permeable to the 
brain-blood barrier, making it applicable to the therapy of central 
nerve system diseases [9].  
The effectiveness of nutraceutical products in preventing diseases 
depends on preserving the bioavailability of the active ingredients. 
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Unfortunately, the concentrations of polyphenols that appear to be 
effective in vitro are often of an order of magnitude higher than the 
levels measured in vivo [10]. The activity and potential health 
benefits of the nutraceuticals, including polyphenols might be 
limited due to insufficient gastric residence time, low solubility 
and/or permeability within the gut, instability under conditions 
encountered in the gastrointestinal tract or processing and 
storage that result in small amount of the molecules available 
following the oral administration [10]. The delivery of these 
compounds therefore requires product formulators to maintain the 
active molecular form up to the time of consumption and preserve 
the stability, bioactivity and bioavailability. These features are the 
central goal of nanoparticle systems [11-12]. 
In this context, the present study aimed to encapsulate luteolin in 
polymeric nanoparticles to overcome the disadvantages of its 
instability, protect the compound and increase its dispersal in 
aqueous medium and thereby improve the bioavailability. The 
nanoparticles which contain luteolin were prepared by interfacial 
polymer deposition following solvent displacement, which is 
known as the nanoprecipitation method proposed by Fessi et 
al.[11]. This method involves the precipitation of a preformed 
polymer from an organic solution and the diffusion of the organic 
solvent in the aqueous medium and allows the preparation of 
nanocapsules (NC) when a small volume of nontoxic oil is 
incorporated into the organic phase or nanospheres (NS) when 
the oil is omitted [11-12]. 
 
Biodegradable nanoparticles are frequently used to improve the 
therapeutic value of various water-soluble/insoluble medicinal 
drugs and bioactive molecules by improving bioavailability, 
solubility and retention time. These nanoparticle–drug 
formulations increase drug efficacy, specificity, tolerability and 
therapeutic index of corresponding drugs. At the same time they 
reduce the patient’s expenses, risks of toxicity and have many 
advantages such as the protection of premature degradation and 
interaction with the biological environment, and enhancement of 
intracellular penetration [13]. 
Novel formulations using the nanoencapsulation method have 
been successful when applied to plant active compounds and 
extracts enhancing stability, sustained delivery and 
pharmacological activity [14]. For example, the nanoprecipitation 
technique using Eudragit®E and polyvinyl alcohol as carriers was 
applied to nanoencapsulate the flavonoid naringenin, reported to 
induce cytotoxicity and apoptosis in various human cancer cell 
lines [15]. Naringenin application in cancer is limited due to low 
aqueous solubility and instability that results in suboptimal 
pharmacokinetics and poor bioavailability at the tumor sites [16]. 
The obtained narigenin nanoparticles showed obvious 
advantages over free naringenin in HeLa cells such as dose-
dependent cytotoxicity, alterations in mitochondrial membrane 
potential, apopptotic morphological changes, increased 
intracellular ROS and lipid peroxidation [17]. Quercetin 
nanoparticles were developed for controlling ischemia-induced 
cerebral oxidative damage using PLA as polymer and 
phosphatidyl ethanolamine. An increased neuroprotective effect 
was demonstrated, such as the protection of endogenous 
antioxidant enzymes against ischemia reperfusion induced 
oxidative damage, when nanoencapsulated quercetin was used in 
comparison with free quercetin or empty nanocapsules [18].  
In addition, injectable daidzein-loaded solid lipid nanoparticles 
(SLNs) with PEGylated phospholipid as stabilizer were prepared 
by the homogenization method to overcome problems related to 
its poor oral absorption and bioavailability in order to improve its 
pharmacological activity on cardio-cerebrovascular diseases. The 
daidzein encapsulated in SLNs could significantly increase 
circulation time compared with orally administrated daidzein or 
intravenoulsy delivered daidzein in solution in Sprague–Dawley 
rats. Furthermore, the daizein-loaded nanoparticles showed a 
better effect on cardiovascular and cerebrovascular systems of 
the anesthetic dogs and a protective effect on rats with ischemia-
reperfusion injury model [19].  
Another successful example is the nanoencapsulation of the 
green tea catechin (−)-epigallocatechin gallate (EGCG), a 
flavonoid that possesses anti-oxidant, anti-inflammatory, 
cardioprotective, neuro-protective and anti-cancer properties, but 
with the therapeutic potential limited by its poor systemic 
absorption following oral consumption due to its degradation in 
gastrointestinal tract. EGCG was encapsulated in chitosan-
tripolyphosphate nanoparticles. It was demonstrated in Swiss 
Outbread mices that the administration of these nanoparticles 
enhanced the plasma exposure of total EGCG by a factor 1.5 in 
comparison with EGCG in solution, and a 2.3 fold increase in the 
apparent exposure of EGCG in jejunum [20].  
Combining both the polymer-based nanoencapsulation technique 
and phythochemicals, including flavonoids may be a useful 
approach for enhancing delivery, stability and bioavailability and 
improving the therapeutic application of these compounds in a 
number of diseases. 
The optimized formulation was identified by using factorial design. 
A 23 full factorial design was carried out. Factorial designs are 
commonly adopted in pharmaceutical research which is 
concerned with the effects of formulation variables and their 
interactions on response variables, yielding the most information 
from small number of experiments. 
Material and Methods 
Luteolin was obtained from Caymann Chemicals (Steinheim, 
Germany). The polymers poly(ε-caprolactone) average Mw 65.000 
and poly(lactic-co-glycolic acid) (65:35) average Mw 40,000-
75,000, oleic acid and the sorbitan monostearate (Span®60) were 
bought from Sigma Aldrich (Steinheim, Germany). Polysorbate 80 
(Tween®80) and isodecyl oleate were obtained from chemistry 
importer Delaware (Porto Alegre, Brazil). The used solvents 
acetonitrile and methanol were HPLC grade purchased from J.T. 
Baker (Phillipsburg, USA). The fosforic acid, sodium chloride, 
potassium chloride, disodium hydrogen phosphate and potassium 
dihydrogen phosphate were obtained from J.T. Baker as well. 
Water was produced in house by Milli-Q System (18M<OMEGA>) 
(Millipore Corporation, Watford, UK).  
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Preparation of nanoparticles 
The nanoparticles were prepared using solvent displacement 
method, which involves the precipitation of a preformed polymer 
(nanoprecipitation) as proposed by Fessi et al. [11]. Briefly, exact 
quantities of polymer, luteolin, span®60 and oil (only in 
nanocapsules) were accurately weighed and dissolved in acetone 
at 45°C. Then, the organic phase was poured into Tween®80 
aqueous solution, which was under moderate magnetic stirring by 
using a peristaltic pump at 10% (PumpPro TPM 600 55RPM, 
Waton-Marlow, Wilmington, UK) at ambient temperature. In due 
course, the colloidal suspension was maintained for 10 minutes 
under moderate magnetic stirring. Subsequently, the solvent and 
the excess of water were removed by using a rotary evaporator 
(R-21, Büchi, Switzerland). The formulations are described in 
Table 1. The final volume of each colloidal dispersion was fixed in 
25mL. 
Experimental design 
The experiments were performed by the nanoprecipitation method 
using a 23 full factorial design. In this experiment, three 
independent variables were studied in two levels: low and high, 
which were represented by the transformed values of –1 and +1, 
respectively. The independent variables were: the kind of both 
polymers and oils and the quantity of luteolin used. The quantity 
of span®60 and tween®80; the volume of the solvent and water, 
and the velocity of both the magnetic stirring and the transfer of 
the organic phase into the aqueous solution were kept constant to 
minimize fluctuations. Values of these selected variables are 
shown in Table 1. The repeatability in the nanoparticle preparation 
was evaluated through Relative-Standard Deviation (RSD%) 
calculations for 3 random formulations prepared in duplicate. The 
dependent variables of factorial design were: pH, particle size 
(PS), zeta potential (ZP), the luteolin absolute recovery (Rec%) 
and its entrapment efficiency (EE%). The best selected 
formulation found was specifically adjusted according to the 
presence (200.0mg, 0.8 % m/v) or not of oil (0.0 mg). The quantity 
of the organic solvent, tensoactives and water were the same as 
described in Table 1, and the amount of Luteolin was 1.25mg.  
Quantification of luteolin content in polymeric 
nanoparticles 
Luteolin was analyzed by High-Performance Liquid 
Chromatography (HPLC). HPLC analysis was performed by using 
an Agilent Technologies Liquid Chromatography 1200 Series 
configured with a degasser G1322A, quaternary pump G1311A, 
autosampler G1329A, column oven G1316A and UV detector 
G1314B. The reversed-phase procedure made use of a stainless 
steel Phenomenex® Gemini C18 column (150x4, 6mm i.d., 5μm 
particle size, s/no 292494-8, Torrance, CA, USA). The control of 
the HPLC system, the acquired and processed data collection 
was performed by Agilent Technologies EZCrom SI software 
(G6702AA, s.n.08021502300). Chromatographic analysis was 
performed in isocratic mode. The mobile phase consisted of 
acetonitrile and formic acid 0.05% (35:65; v/v). The flow rate was 
1.2 mL min-1 for 6 min with an injection volume of 20µl. All 
experiments were performed at 220 nm and the column 
temperature was maintained at 35°C.  
Preparation of standard and sample solutions for 
method validation 
Primary stock standard solution of luteolin (1.00µg mL-1) was 
prepared by accurately dissolving 10.0mg of luteolin into 10.0mL 
of methanol in a volumetric flask (Pirex®). The working solution 
(100µg mL-1) was obtained by diluting 10 times the standard 
solution into methanol. The sample curve solutions were prepared 
by diluting the working solution to 5.00, 10.0, 20.0, 40.0, 60.0, 
80.0 and 100µg mL-1. They were obtained by mixing a sufficient 
quantity of the working solution into methanol towards a final 
volume of 1.00mL. All solutions and dilutions were prepared in 
triplicate. These solutions were used to perform the calibration 
curve, linearity, range, limit of detection (LOD) and limit of 
quantification (LOQ) of the method. Three other solutions (6.00, 
50.0 and 90.0µg mL-1) were prepared in quintuplicate in the same 
way in order to investigate the accuracy and precision of the 
method. The linearity was determined through the calculation of 
the linear regression from the peak area vs. the concentration plot 
of the seven standard solutions using the linear least squares 
methodology, and through the analysis of respective response 
factors (i.e. the peak area divided by the concentration of each 
standard sample). The limits of detection (LOD) and quantification 
(LOQ) were mathematically calculated through the relation 
between the standard deviation (sd) of the calibration curve and 
its slope (S), by using the multiplier suggested in the ICH standard 
[21]. The LOD and LOQ were calculated from the following 
equations:  LOD = [ 3.3 x sd / S ]  and LOD = [ 10 x sd / S ]. 
Pretreatment of luteolin samples for HPLC analyses 
 In order to obtain real quantitative values of luteolin in 
colloidal suspension, it was necessary to develop two different 
pretreatment methods; a specific one to assay the total content of 
luteolin in colloidal suspension (Rec%), and another one to 
quantify the luteolin associated with the nanoparticles (EE%). The 
total content of luteolin was determined by the opening of 
nanoparticles dispersed in a colloidal suspension, following the 
procedure described below: 0.9mL of acetone was added to 
0.1mL of colloidal suspension and left to rest for 2 hours. After the 
resting period, the solution was subjected to centrifugation at 
14,000rpm for 30min at 30°C (Centrifuge 5810 R, Eppendorf®, 
Hamburg, Germany). Finally, 0.5mL of solution was dried in 
Speedvac (Savant Speedvac Plus SC 10 A, Farmingdale, USA) 
and the luteolin was resuspended in 0.2mL of methanol being 
analyzed by HPLC. 
The entrapment efficiency of luteolin nanoparticles was 
determined by analyzing the concentration of the free unloaded 
compound in the aqueous phase of the colloidal suspension. 
Centrifugation was carried out using the cellulose acetate tube 
filter of the 0.22μm pore membrane (Costar®Spin-X®, Corning 
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Inc.).  Approximately 0.5mL of nanoparticle dispersion was placed 
into the outer chamber of the filter assembly. The assembly was 
then centrifuged at 5,000rpm for 15min at 15ºC. The 
nanoparticles along with the encapsulated compounds remained 
in the outer chamber whereas the aqueous dispersion medium 
containing the free unloaded compounds were moved to the 
sample recovery chamber through the filter membrane. After 
separation, 0.3mL of aqueous dispersion medium was dried.  
Finally, the product was resuspended in 0.2mL of methanol and 
the amount of the free luteolin in the dispersion medium was 
estimated by HPLC. The entrapment efficiency was subsequently 
calculated as the equation follows: EE% = [(total quantity of 
luteolin – quantity of free luteolin in the aqueous medium) / total 
quantity of luteolin] x 100. 
Characterization of suspensions 
The physicochemical analysis of nanoparticles was carried out 
immediately after their preparation. After preparing all the colloidal 
suspensions, the pH values were determined by using a 
potentiometer (B474 Micronal, São Paulo, BR). The analyses of 
the particle size (PS) of the nanoparticles were performed by 
photon correlation spectroscopy (PCS). The PCS measurements 
in nanometers were carried out at room temperature at a fixed 
angle of 90°. This technique yields the mean particle 
hydrodynamic diameter (PS) and the polydispersity index (PI), 
which are a dimensionless measure of the broadness of the PS 
distribution. The values of both the PS and the ZP were measured 
by using Zetatrac (Microtrac Inc., USA), which was controlled by 
Microtrac Flex V.10.5.0 software (Microtrac Inc., USA). For PCS 
and zeta potential (z, milivoltz) measurements, 0.1mL of each 
colloidal suspension was diluted into 10.0mL of ultrapure water 
and 10mM NaCl, respectively. The values reported are the mean 
values for each nanoparticle formulation. These measures were 
carried out at 25°C. 
The nanoparticles were dried on a polished metal support and 
then gold-sputtered; afterwards, they were examined by the 
Scanning electron microscopy (SEM) (Philips XL 30 FEG) at 10 
kV, using different magnifications until 10,000 times.  
In vitro release studies of luteolin from nanocapsules 
In vitro release studies of luteolin from nanocapsules in colloidal 
suspension were carried out after some changes in the dialysis 
bag diffusion technique, previously described by Levy and Benita 
(1990) [22]. Dialysis bags (Dialysis tubing cellulose membrane, 
0.4 in, Sigma) with 1.0mL of the luteolin colloidal suspension were 
sealed and dropped into 1L of phosphate buffered saline (PBS) at 
pH = 7.4. This solution was kept under continuous magnetic 
stirring. The PBS was prepared by dissolving the following salts: 
8.00g NaCl; 0.20g KCl; 1.44g Na2HPO4.2H2O and 0.24 g of 
KH2PO4 for each liter of distilled water. The whole system was 
kept at 35°C and on continuous stream at 3.0mL min-1. The 
stream was controlled by a peristaltic pump (PumpPro TPM 600 
55RPM, Waton-Marlow, Wilmington, UK). At given time intervals, 
a dialysis bag was withdrawn from the stirred releasing medium 
and the luteolin content was directly assayed by the previously 
validated HPLC method. The values reported were the mean 
values corresponding to three different batches. 
Results and Discussion  
Characterization of polymeric nanoparticles loaded 
with luteolin 
The nanoprecipitation method was conducted through the 
precipitation of a preformed polymer from an organic solution 
which was previously solubilized, with the diffusion of this organic 
solvent into the aqueous medium. In the aqueous phase, the 
polymers get insoluble, precipitating immediately leading to the 
formation of nanoparticles [11]. All formulations presented a 
macroscopic homogeneous aspect of a bluish white milky 
opalescent fluid (Tyndall effect) as a result of the nanoparticle 
formation as soon as the acetone was diffused into the aqueous 
phase, in agreement with the results previously reported in 
literature for other nanoparticle systems [11,23]. This observation 
confirms the formation of nanoparticles. This technique proved to 
be simple as well as easily reproducible.  
An important result obtained in this work was the increase luteolin 
dispersion in water. The low solubility of luteolin may result in its 
poor permeation across the intestinal epithelial cells and 
gastrointestinal tract, which may compromise its clinical efficiency. 
In the formulations proposed for this study, it was possible to 
prepare colloidal suspension containing up to 100µg mL-1 
(349.4µM) of the luteolin. This result is 75% higher than the water 
dispersion of luteolin obtained by Kim et al. (2008) through 
cyclodextrin complexation [24].  
Analytical validation HPLC method 
Reliable analytical data are a prerequisite for the correct 
interpretation of nanoparticle characteristics when under 
evaluation. The investigation upon of Rec%, EE% and kinetic 
release was just possible by using the HPLC method. The 
applicability of the method was checked by analytical validation 
according to the International Conference on Harmonization [21]. 
The specificity of the method was evaluated by comparing the 
chromatogram analyses of prepared nanoparticle samples 
containing and not containing the luteolin (Figure 2). No interfering 
peak was observed in 3.87min in the blank chromatogram 
(retention time of luteolin) in a work wavelength of 220 nm. In this 
sense, the method may be considered to be specific for the 
desired analysis since no interference peaks were observed. 
The analytical calibration curves  (n = 3) were linear over the 
concentration range from 5.00 to 100µg mL-1 (Figure 3). The 
linearity was assessed through calculating the regression 
equation (y = a.x ± b) and the correlation coefficient (r2) by the 
least squares method, where: y = 89.19(±0.07).x – 67.21(±26.03) 
and r2 = 0.9999. The y is the area of chromatographic peak, and x 
the concentration of standard solution in µg mL-1. The standard 
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deviations of the values of a and b are indicated in parentheses. 
The r2 value which is greater than 0.999 indicates a good linearity 
for the range of the proposed work. The quality of linearity was 
also evaluated through the analysis of the response factor (Figure 
3). The response factors revealed a 5.50% RSD among all levels 
of concentration patterns. Therefore, samples may be adequately 
analyzed within the concentration range of the proposed method. 
Accuracy was analyzed by calculating the average percentage 
recoveries for the Luteolin at three different concentrations (6.00, 
50.0 and 95.0µg mL-1). These solutions were used to calculate 
both precision and accuracy. The precision was represented by 
Relative Standard Deviation (RSD). RSD for repeatability at each 
concentration level of standard solutions intra-day (n = 15) and 
inter-day (n = 3) were lower than ≤3.68% and ≤2.79%, respectively. 
These results indicate good precision of the analytical method. 
The total Rec% (accuracy) and its RSD found were 97.7±2.15%, 
showing strong agreement between the experimental and 
theoretical values. Detailed results for the three concentration 
levels which were tested are shown in Table 2. 
The LOD and LOQ were calculated in accordance with the 
intercept standard deviation (sd = 21.91) and the slope of the 
calibration curve (S = 89.19). They were found to be 0.81 and 
2.45µg mL-1, respectively. The validated method was successfully 
applied in the evaluation of both the Rec% and the EE% of 
luteolin in polymeric nanoparticles. The pretreatments showed to 
be effective for the desirable analyses. It was possible to obtain 
recoveries up to 100% with regard to the linear calibration curve. 
These results are fundamental to analyze whether the target 
analyte was efficiently nanoencapsulated, its solubility and 
stability increased, as well as the kinetic release and the tested 
formulation efficacy. The quantitative results are described in 
Table 3. 
Factorial design evaluation for Luteolin formulations  
Biological action of several herbal medicines can be modified in 
agreement with their formulations. Their solubility, gastrointestinal 
stability and release profile can be improved by controlling the 
type of formulation employed. In this case, studies to prepare 
efficient formulations are necessary whenever the best features of 
nanoparticles are desired. Thus, the aim of this study was also to 
develop and evaluate processes and parameters to prepare 
nanoparticles loaded with luteolin by using factorial design.  
The 23 factorial design had three independent variables which 
resulted in eight experiments. Furthermore, other three random 
experiments (02, 04 and 07) were carried out in order to evaluate 
the method capacity of reproducing the results. Thus, the total 
number of experiments was eleven. The analysis of the 
experimental scattering revealed a good reproducibility. Data 
dispersion for all dependent variables was smaller than 4.4% 
showing satisfactory repeatability of the nanoparticle preparation 
process. In this way, the experimental variations among the 
formulations were considered to be existent just when the 
calculation effects were higher than 4.4%. 
In these experiments, the ideal type of polymer and oil, the 
quantity of luteolin to obtain the best colloidal dispersion and 
luteolin stability were evaluated. The fixed variables which are 
described in Table 1 were kept constant. Their quantitative values 
were previously defined prior to the literature review [23], another 
group work [25] and experimental compatibility evaluation for 
luteolin.  
The polymers evaluated, PCL and PLGA, are often employed as 
support to deliver drugs, either as NS (monolithic devices) or NC 
(reservoir devices). These polyester polymers have widely been 
used by the pharmaceutical industry because of their 
biocompatibility, dissolution capacity into organisms and 
mechanical properties which are suitable for such applications, 
and their biodegradability by micro and macroorganisms [26,27]. 
The spherical shape of nanoparticles was confirmed by using the 
scanning electron microscope (SEM). In order to obtain good 
resolution through SEM, it was necessary to remove all the water 
from the colloidal suspensions after they were added to the 
polished metal support. This process caused the gathering of 
nanoparticles and a polymeric pellicle was formed as a result. 
However, it was possible to observe remaining nanoparticles on 
the polymeric pellicle (Figure 4). The morphological analysis 
through SEM revealed that nanoparticles prepared by using 
isodecyl oleate had a better formation of spherical particles which 
shown regular surface and form, homogeneity, and lower 
dispersion in their sizes. On the other hand, nanoparticles 
prepared by using oleic acid shown poor formation of particles 
with higher dispersion in their sizes. It is likely that nanoparticles 
prepared by using oleic acid were less stable in both processes: 
the nanoparticle formation and the drying onto polished metal 
support. The formed negative charge in the edges of produced 
micelles when oleic acid is applied can justify the loss in colloidal 
dispersion stability.  
The photomicrographs obtained did not show formation of 
crystals. Crystals may grow when the compound to be 
nanoencapsulated exceeds its solubility level or due to a great 
difference between the particle sizes. The absence of the crystals 
was confirmed by SEM, Rec% and EE% of the method. 
The dependent variables utilized to investigate the colloidal 
dispersion were pH, PS, PI and ZP. On the other hand, the 
dependent variables, Rec% and EE%, were applied in the stability 
and kinetic release studies. The results of dependent variables 
are illustrated in Table 3. 
The effect of each variable and their interactions were calculated 
according to the following equation: Effect of variable = + – –, 
where + and – are the average of pH, PS, ZP, Rec% and EE% 
at the higher (coded as +1) and lower (coded as –1) levels, 
respectively. Figure 5 shows the calculated effects for the 
standard data for the performed 23 factorial design. On 
normalization the greatest values were taken as 100 and the rest 
were scaled proportionately. 
The oils utilized are two potent chemical permeations which are 
widely used in commercial formulations. Isodecyl oleate 
(C28H54O2) is neutral-water insoluble ester (no-ionic) which is 
employed as emulsifier and it can favor the substance inclusion 
as well as improving the active compound stability. In addition, it 
is a well-known emollient showing fluidity and causing no irritation 
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when widely used in skin formulations [28]. On the other hand, the 
oleic acid (C18H34O2) is a monounsaturated fatty acid anionic 
which is used as a tensoactive forming micelles in aqueous 
phase. Two specific quantities of luteolin were investigated in 
order to evaluate its stability through Rec%, and the EE% during 
the preparation of nanoformulations. 
The pH value is directly related to formulation compounds. The 
type of polymer and oil could cause effects in pH values. The pH 
values ranged from 5.3 to 5.7. However, regardless the prepared 
formulation or evaluated interaction effects, no significant effect 
was observed. This can be indicated by the small slope of the 
arrows in Figure 5A. 
The PS can have important consequences in pharmaceutical 
applications for nanoparticles. Initially, all formulations were 
prepared by using oil which led to the preparation of only 
nanocapsules which showed average particle sizes of 130.6 nm. 
The range in PS values was from 72.4 to 185.5 nm. Although the 
types of the oils utilized in this work were different from the ones 
normally applied in literature (caprylic/capric triglyceride, mineral 
oil, etc.), the PS results are in agreement with previous studies 
described in literature which applied the nanoprecipitation 
technique, i.e., nanocapsules with PS smaller than 300 nm 
[23,29]. As so far isodecyl oleate and oleic acid have not been 
reported to prepare polymeric nanoparticles loaded with 
flavonoids. The PS in NC is limited by the size of the drops which 
are immediately created (oil core) when the organic phase is 
transferred into the aqueous phase. The oil core is controlled by 
the flow through which the organic phase is poured into aqueous 
solution, as well as the magnetic stirring and viscosity of the 
aqueous phase [29]. These factors have not undergone 
variations. In this case, the main particle size variations only 
depended on the type of polymers (PCL and PLGA) and oils 
(isodecyl oleate and oleic acid) used. In due course, through the 
calculation of the effects, it was possible to observe that PLGA 
and oleic acid decreased 16.9% and 33.6% the PS value, 
respectively (Figure 5C). Oleic acid is a cis-monoinsatured fatty 
acid which reduces the diameter of micelles. PLGA may form 
mainly dipole-dipole interactions with PLGA or with other groups, 
and PCL may make Van der Waals interactions as a rule. These 
different intermolecular interactions may lead to a singular way of 
how the polymers precipitate into the aqueous phase. However, 
by analyzing the calculation of the effects for the interactions of 
2nd and 3rd-order (x1.x2; x1.x3; x2.x3 and x1.x2.x3), it could be 
observed that only the interaction between the higher luteolin 
quantity and PLGA showed a slight increase (13.1%) in PS value. 
This effect is observed when the quantity of luteolin and the type 
of oil are at the same level (1.25mg luteolin-isodecyl oleate or 
2.50mg luteolin-oleic acid). Thus, both types of oils and polymers 
could be used to prepare nanocapsules smaller than 250nm 
loaded with luteolin. 
Regarding the size of nanoparticles, not only is their average 
value (nm) important, but also their size variability. A metric for 
size variability is the PI, a unitless quantity derived from the 
cumulate analysis and equivalent to the relative variance of the 
distribution [30]. In other words, the PI represents the 
homogeneity of nanoparticle size distribution. All formulations 
obtained a PI lower than 0.200. The PI average was 0.110, and 
the highest was 0.144. Values of polydispersity index lower than 
0.200 describe narrow-average distribution and are considered to 
be a homogenic suspension. They are desired to keep the 
stability of colloidal dispersion without the formation of 
microparticles or precipitates [31]. The colloidal suspensions 
prepared using PCL, PLGA didn’t precipitate even after five 
months. This narrow particle size distribution circumvents creation 
of luteolin concentration gradient between small and large 
nanoparticles which could lead to luteolin crystallization onto large 
particles, i.e., crystal growth known as Ostwald ripening [32]. 
Zeta Potential, likewise PS and PI, is a very important parameter 
in order to evaluate the colloidal suspension. When nanoparticles 
are prepared, the formation of an electrical double layer occurs 
surrounding the nanoparticles when in solution. The electrostatic 
potential at this “slipping plane” boundary is called the zeta 
potential and is related to the surface charge of the nanoparticle 
[33]. Accordingly, the zeta potential indicates the degree of 
repulsion between similarly charged particles in dispersion and it 
is a parameter widely used to predict colloidal suspension 
stability. Nanoparticles with a zeta potential between +10 and –10 
mV are considered approximately neutral. On the other hand, 
nanoparticles with ZP higher than +30 mV or lesser than –30mV 
are considered to be very stable in the dispersion medium [32-33].  
The formulations showed zeta potential ranging from 12.7 to 32.6 
mV (using values in module). Two main effects were observed: all 
formulations prepared by using oleic acid have a positive ZP 
value, and the PLGA decreased the ZP in 42.3%, as it could be 
seen through the calculation of the effect between PCL and PLGA 
interaction. For this reason, PCL was considered to be better than 
PLGA at preparing stable colloidal suspension. The use of oleic 
acid caused a slight increase in ZP (8.6%). No other calculation of 
the effect showed significant effect over ZP.  
For pharmaceutical use, a colloidal suspension must have a 
minimal tendency to agglomerate, which could create a hard 
cake. For this reason, tween®80 was used as steric stabilizer [32].  
The absolute average recovery was 80.9%, and the lower and the 
higher values were 61.6 and 94.3%, respectively. The main effect 
was observed for the independent variable “quantity of luteolin” 
which showed a decrease of 12.4% when the amount of luteolin 
increased from 1.25 to 2.50mg. The 2nd order (x1.x2) interaction 
also depicted a reduction of 11.0% when the independent 
variables x1 and x2 were at the same level, i.e., PLC/1.25mg of 
luteolin or PLGA/2.50mg of luteolin. However, the 3rd order 
(x1.x2.x3) interaction did not show significant variations. 
Regardless the Rec% observed, there was no difference in EE%. 
All formulations showed an entrapment efficiency greater than 
97%. The concentration of luteolin did not influence this variable. 
This result is a consequence of the low solubility of luteolin, which 
prefers both the oily core and polymeric interaction instead of the 
aqueous medium. As a consequence, the formation of colloidal 
dispersion increases the dispersion of luteolin in the aqueous 
medium. 
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In view of such results and the calculated cost, the best 
formulation was defined by using PCL and isodecyl oleate.  
Afterwards, the features of nanoparticles in the presence (NC) or 
not (NS) of isodecyl oleate, formulations 09 and 10, respectively, 
were investigated. Both experiments showed Rec% and EE% 
higher than 89.1% (Table 4). The main difference was the particle 
size between nanocapsules and nanospheres. The nanospheres 
were nearly 50% smaller. A slight improvement could also be 
observed in nanocapsules regarding the ZP, Rec% and EE%. 
Thus, the best formulation may be selected evaluating PS and by 
the physiological barriers which the nanoparticles need to 
transpose.  
Release kinetics 
The release assays of the formulations 09 and 10 were carried 
out in PBS medium at 35°C, which was kept under magnetic 
stirring and continuous stream to avoid saturation of the system. 
In this assay, the luteolin passes through the pores of the 
membrane while the nanoparticles do not, hence allowing the 
observation of the luteolin diffusion. The PBS butter and 
controlled temperature were selected in order to imitate the 
human biologic system. During the assay, aliquots were collected 
at pre-established times and the luteolin was quantified by HPLC. 
The results were expressed in terms of the percentage release 
(Figure 6).  
The release profiles of NC and NS were similar and did not show 
statistic difference. The percentage of luteolin, which was 
released at the first sampling time of 0.5 hour were 34.5 and 
43.1% for NS and NS, respectively. These two formulations 
revealed a fast release kinetic during the first two hours, which 
was approximately 63%. Such a fact probably occurs through the 
fast migration of luteolin adsorbed on the polymeric nanoparticle 
surface or positioned in the superficial polymeric layer [34]. After 
four hours, the formulations showed constant and slow release 
rate, probably because of the existence of internal interactions 
between luteolin and the polymer of the nanoparticles [34]. As a 
result, there may be a reduction on the release rate. Naturally, this 
behavior took place in the continuous stream at 3.0mL min-1. The 
total percentage of release after fifteen hours for both formulations 
was 87%.  
Mathematical modeling (zero order, first order, biexponential) was 
applied to obtain information about the kinetics of luteolin 
dissolution and release behavior. After adjusting these models, 
the best profile was selected based on the highest correlation 
coefficient (r2). According to these criteria, the zero order was the 
best model to describe the dissolution and release profiles for 
nanoencapsulated luteolin, showing two specific tendencies: a 
fast one between 0 and 2 hours, and another slow one between 2 
and 15 hours. In face of this result, the release behavior from 
nanocapsules of PCLwas determined through the theoretical 
model of Korsmeyer-Peppas for drugs release in polymeric 
systems [35]. This model is applied for anomalous behaviors of 
release, which was described by Mt /M¥ = K.tn where Mt /Mµ is a 
fraction of release in a given time t, n and K are the exponent of 
liberation and release factor, respectively [35]. Korsmeyer-
Peppas’s model is usually used to analyze the release of a drug 
of a polymeric matrix when the release behavior is not well known 
or when one or more types of phenomena are involved.  
The construction of the graph through ln(Mt/M∞) in function of ln(t) 
provides the exponent (n) and the release constant (K, time-n). 
The empiric values of n, which were determined for luteolin in NS 
and NC, were 0.387 and 0.267, respectively, were obtained from 
the initial portion of the curve (%released < 80%).  The release 
constants were 0.963 and 0.994, respectively. When the n values 
are smaller than 0.45 (n £ 0.45), the mechanism of release refers 
to a process of pure diffusion (Fickian diffusion) [35]. 
Nanoparticles loaded with luteolin depicted n £ 0.45 in 
accordance with the zero order mechanism, which was previously 
observed. 
Conclusions 
The results from our study show that homogeneous nanoparticle 
suspensions loaded with luteolin can be prepared through 
preformed polymers by using interfacial polymer deposition 
following solvent displacement. The prepared formulations and 
their physico-chemical characteristics were evaluated through 
factorial design. The polymers PCL and PLGA, oils isodecyl 
oleate and oleic acid, as well as the charge of luteolin were 
investigated. This strategy allowed us to prepare stable colloidal 
suspensions. The nanoparticles were obtained mainly by use of 
PCL and isodecyl oleate. Small, spherical and submicron sized 
nanoparticles were obtained. The range in PS values for NC was 
from 72.4 to 185.5 nm. NS showed an average particle size of 
77.3 nm. 
In order to characterize the Rec% and EE% in colloidal 
suspension, a HPLC method was developed and validated. This 
method allowed the assessing of the occurrence of loss and 
degradation processes of luteolin, EE% and the kinetic release. 
The method showed a limit of quantification of 2.45µg mL-1. It was 
also possible to prepare colloidal suspensions containing up to 
100µg mL-1 (349.4µM) of the luteolin. The Rec% (luteolin content) 
and EE% were higher than 90 and 98%, respectively, in the best 
formulations. 
The suggested method of dialysis for the analysis of kinetic 
release of luteolin was efficient and showed reproductive results 
in vitro. It could be used in routine experiments. Luteolin release 
from nanoparticles appeared to have two components: an initial 
rapid release, due to surface-associated luteolin, followed by a 
slower exponential release of the luteolin dissolved in the core.  
NC and NS of PCL depicted the same release profile. These 
nanoparticles are quite stable in aqueous dispersion and can be 
further optimized to be used as an efficient luteolin delivery agent. 
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Table 1. Investigated variables in polymeric nanoparticles formulations loaded with luteolin 
evaluated in 23 full factorial design. 
 
Variables Low level ( – 1) High level ( + 1) 
x1, Polymer 
75.0 mg (0.3 % m/v) 
PCL PLGA 
x2, Luteolin 1.25 mg (0.005 %, m/v) 2.50 mg (0.010 %, m/v) 
x3,Oil 
300.0 mg (1.2 % m/v) 
Isodecyl oleate Oleic acid 
Fixed variables 
Acetone volume 14,0 mL 
Span®60 40.0 mg (0.16 %, m/v) 
Aqueous phase 
volume 
27,0 mL 
Tween®80 40.0 mg (0.16 %, m/v) 
PCL: poly(ε-caprolactone) PLGA: poly(lactic-co-glycolic acid). (%, m/v): after the organic solvent was removed and the final 
volume water fixed in 25mL. 
 
 
 
 
 
 
Table 2. Results of precision and accuracy intra and inter days, for three different concentrations 
of luteolin. 
 
 
Nominal 
Concentration 
(µg mL-1) 
Precisiona Accuracy 
Day 1 
(n = 5) 
Day 2 
(n = 5) 
Day 3 
(n = 5) 
Inter – Day 
(n = 15) 
 Conc. µg mL-1/ RSD (%) (%) 
6.00 5.87/1.27 5.65/3.41 5.99/3.68 97.3 
50.0 48.09/0.30 48.38/1.20 50.41/2.47 97.9 
95.0 92.27/0.47 92.31/0.39 94.85/0.31 98.0 
a Mean concentration found (µg mL-1)/RSD. 
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Table 3. Characterization of luteolin loaded PCL and PLGA nanocapsules prepared through 23 
full factorial design. 
 
Exp Independent 
variables 
Dependent variablesa 
x1 x2 x3 pH PS (nm) ZP (mV) (Rec%) (EE%) 
01 –1 –1 –1 5.57±0.09 185.5±6.38 -28.4±0.7 82.2±3.0 97.8±1.0 
02 +1 –1 –1 5.73±0.11 165.9±4.01 -16.0±0.5 94.3±1.7 98.0±1.2 
03 –1 +1 –1 5.69±0.09 157.2±5.55 -29.4±0.9 75.3±2.2 98.8±1.8 
04 +1 +1 –1 5.53±0.17 138.1±5.03 -12.7±0.8 61.6±1.8 98.5±1.6 
05 –1 –1 +1 5.48±0.04 106.0±5.09 32.6±1.1 85.0±2.9 97.6±1.6 
06 +1 –1 +1 5.38±0.07 72.4±6.37 18.8±0.5 85.6±0.7 98.0±2.2 
07 –1 +1 +1 5.30±0.10 136.3±8.68 29.6±0.6 89.2±1.5 98.8±0.8 
08 +1 +1 +1 5.45±0.08 83.0±7.09 16.7±1.1 74.1±1.4 98.7±0.3 
aTriplicate mean values of analyses and their standard deviations (mean±SD). PS, particle size; ZP, zeta potential; 
REC%, absolute recovery and; EE%, entrapment efficiency. 
 
 
 
 
Table 4. Characterization of nanocapsules and nanospheres of PCL polymer loaded with luteolin. 
 
Experiment pH PS (nm) ZP (mV) (Rec%) (EE%) 
With oila 5.77±0.13 161.8±6.61 -31.2±0.7 89.1±1.4 90.2±7.5 
Without oil 5.89±0.15 77.3±4.01 -26.5±0.5 94.7±5.8 95.0±0.1 
aOil: isodecyl oleate. Triplicate mean values of analysis and their standard deviations 
(mean±SD) 
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Figure 1. Luteolin structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Typical chromatogram of a colloidal dispersion of polymeric nanoparticles with and 
without (blank) luteolin. 
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Figure 3. Linearity for the quantitative method to Luteolin analysis by HPLC. (■) Calibration 
curve obtained with luteolin standard solutions (n = 21); (●) Luteolin response factor vs. 
concentration of luteolin standard solution (n = 21). 
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Figure 4. Scanning electron microscope images of nanocapsules containing (A) PLC/isodecyl 
oleate; (B) PCL/oleic acid; (C) PLGA/isodecyl oleate and (D) PLGA/oleic acid. The 
photomicrographs were taken with 10,000 x magnification. 
 
 
(A) (B)
(C) (D)
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Figure 5. Calculated effects of the experiments performed by 23 factorial designs. Arrows inside 
the figure represent the calculated effects in percentage after normalization of the data. It is 
important to observe that the inclination of the arrows indicates the amplitude of the effects. 
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Figure 6. In vitro release profile of luteolin from (■) nanospheres and (●) nanocapsules. 
 
 
0 2 4 6 8 10 12 14
0
20
40
60
80
100
Pe
rc
en
t D
ru
g 
R
el
ea
se
d
Time (h)
 Nanospheres
 Nanocapsules
